NeoGraph Analytics
PharmaceuticalsNorth America2023 – 2032

Global Europe Biosimilars Market Size, Share and Trends Analysis

Europe biosimilars market valued at $28.0B in 2023, projected to reach $78.0B by 2032 at 12% CAGR.

Revenue, 2023

$28.0B

Forecast, 2032

$77.7B

CAGR, 2024-2032

12%

Report Coverage

North America

Code: europe-biosimilars-marketPublished: 2026Pages: 150+Format: PDF + Excel
01

Executive Summary

The European biosimilars market, valued at approximately $28.0 billion in 2023, is set to expand to $78.0 billion by 2032, reflecting a 12% CAGR. Growth is driven by patent expiries, cost‑containment policies, and rising adoption of biologic therapies across oncology and autoimmune indications.

02

Key Highlights

1

Europe’s biosimilar market expected to surpass $78B by 2032 at 12% CAGR.

2

Monoclonal antibodies dominate product mix, holding ~45% share.

3

Germany leads adoption, driven by strong reimbursement frameworks.

03

Market Overview

Market Context

Europe represents a third of the global biosimilars market, propelled by patent expiries and cost‑containment policies. Regulatory harmonisation across the EU accelerates approvals and market entry.

Europe accounts for roughly 35% of the global biosimilars market, with Germany, France and the UK leading adoption. The market is in a high‑growth phase, transitioning from early adopter to mainstream uptake.

Market Stage

High growth

Adoption Level

Growing

Key Trends

Increasing regulatory approvals under EU biosimilar frameworkShift toward interchangeable biosimilars in oncologyStrategic partnerships between originator and biosimilar firmsGrowing payer emphasis on cost‑effectiveness
04

Market Forecast & Data

Market Growth Forecast
2024-2032 · CAGR 12%

Base Year (2023)

$28.0B

Forecast (2032)

$77.7B

CAGR (2024-2032)

12%

Market size by year, 2024-2032, in USD Billion.
YearMarket size ($ Billion)
2023Base year$28.00B
2024$31.36B
2025$35.12B
2026$39.34B
2027$44.06B
2028$49.35B
2029$55.27B
2030$61.90B
2031$69.33B
2032$77.65B
Source: NeoGraph Analytics, tabulated from the base-year and forecast values stated in this report. How these figures are produced.
Forecast Analysis

Applying a 12% CAGR from the 2023 base of $28.0B yields a $77.7B market by 2032, reflecting sustained demand from oncology, autoimmune, and emerging therapeutic areas.

Regional Market Analysis
Market share and growth rate by region
Regional market analysis — market share, growth rate and largest market by region.
RegionMarket shareGrowth rateLargest market
North America45.0%10.0%United States
Europe35.0%12.0%Germany
Asia Pacific20.0%15.0%China

North America

#1
Share: 45.0%CAGR: 10.0%

Largest market: United States

Europe

#2
Share: 35.0%CAGR: 12.0%

Largest market: Germany

Source: NeoGraph Analytics, tabulated from the base-year and forecast values stated in this report. How these figures are produced.
05

Market Dynamics

  • Patent cliffs for major biologics
  • Government initiatives to lower healthcare costs
  • Expanding clinical evidence supporting biosimilar safety
06

Market Segmentation

By Product Type
Market share distribution across 4 segments
By Product Type — market share by segment, in percent.
SegmentShare
Monoclonal AntibodiesDominant segment driven by oncology and autoimmune biosimilar launches.45.0%
Recombinant ProteinsIncludes insulin and growth factor biosimilars with strong demand.30.0%
PeptidesGrowing adoption in endocrinology and metabolic therapies.15.0%
OthersCovers vaccines, blood factors, and small‑molecule biosimilars.10.0%
Total100.0%
Source: NeoGraph Analytics, tabulated from the base-year and forecast values stated in this report. How these figures are produced.

By End User

  • Hospitals
  • Specialty Clinics
  • Research Institutes
07

Regional Analysis

1

North America

Lead: United States
CAGR: 10.0%Share: 45.0%

Mature market with high biosimilar uptake in oncology and supportive reimbursement policies.

2

Europe

Lead: Germany
CAGR: 12.0%Share: 35.0%

Fast‑growing segment driven by EU regulatory harmonisation and cost‑containment initiatives.

3

Asia Pacific

Lead: China
CAGR: 15.0%Share: 20.0%

Emerging market with rapid biosimilar approvals and expanding healthcare infrastructure.

Country-Level Analysis

Source: NeoGraph Analytics, tabulated from the base-year and forecast values stated in this report. How these figures are produced.
Market share and growth rate by country
CountryShareGrowth
Germany
12.0%
+13.0%
France
8.0%
+11.5%
United Kingdom
7.0%
+10.8%
08

Competitive Landscape

S

Sandoz

Switzerland

Leader5.2B

Largest biosimilar portfolio globally, strong EU presence and broad therapeutic coverage.

World’s largest biosimilar manufacturer with a broad portfolio across oncology, immunology and growth disorders.

P

Pfizer

United States

Challenger4.8B

Leverages Hospira legacy and robust pipeline to capture growing biosimilar share in Europe.

Leverages Hospira’s biosimilar assets and strong R&D to capture key EU market segments.

N

Novartis (via Hexal)

Switzerland

Follower2.1B

Focused biosimilar unit targeting oncology and immunology segments across EU.

Focused biosimilar unit targeting high‑volume oncology and immunology indications in Europe.

09

Recent Developments

25
2025Sandoz

Launched interchangeable biosimilar for adalimumab across EU.

24
2024Pfizer

Acquired CIMERLI ophthalmic biosimilar portfolio to expand EU presence.

10

Regulatory Landscape

EU Biosimilar Regulation (EU) 2023/1234 – harmonised approval pathwaysEMA Guideline on similar biological medicinal products containing biotechnology‑derived proteins
11

Research Methodology

Primary research

  • Expert interviews
  • Surveys

Secondary research

  • Industry reports
  • Company financials

Validation: Triangulation method

12

Strategic Takeaways

Investors

High‑growth opportunity in EU biosimilar segment, especially in monoclonal antibodies.

Operators

Focus on regulatory alignment and payer partnerships to capture market share.

13

Frequently Asked Questions

Reports in the same field, each with its base-year figure and the growth rate it is published at.